PK-PD platform 2.0

At a Glance
  • Status: Active Consortium
  • Year Launched: 2012
  • Initiating Organization: Top Industry Pharma
  • Initiator Type: Nonprofit foundation
  • No disease focus
  • Location: Europe


The mechanism-based PK-PD modeling platform 2.0 aims to develop novel mechanism-based PK-PD modeling concepts for stationary and nonstationary biological systems and builds on the mechanism-based PK-PD modeling platform 1.0. The research program is a systems pharmacology approach, which focuses on the development and application of novel mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling concepts.


The goal of the research program is to develop a mechanism-based PK-PD model library together with a knowledge-based management system to securely store preclinical, clinical, and epidemiological data and to support future model-based research in drug discovery and development

This research program will yield a mechanism-based PK-PD model library and database, which can be used for (a) drug candidate selection, (b) design and evaluation of early proof-of-concept studies in man, (c) optimization of Phase III clinical trials, and (d) prediction of long-term outcome of drug treatment. In addition to the generation of models the platform educates a new generation of PK-PD modelers.

Consortium History

November 2012:  Project began
November 2017:  Project scheduled to end


Points of Contact

Principal Investigator: Meindert Danhof

Sponsors & Partners


Erasmus MC


Leiden University



TI Pharma

University of Groningen

Last Updated: 04/08/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.